Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with DTR 3.1.4R(1)(a).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting a specific share acquisition event.
- Share Acquisition Price: 1367.57 pence per Share.
- Transaction Date: Shares acquired following dividend reinvestment paid on January 14, 2016.
- Plan Type: GSK 2009 Deferred Annual Bonus Plan Post-Tax.
Material Changes
The filing details a change in the shareholding interest of Ms. C Thomas, a PDMR. No material changes to the company's financial position or operations are reported in this document.
- Ms. C Thomas Acquisitions:
- 37.982 Ordinary Shares (Personal contribution element).
- 38.185 Ordinary Shares (GSK matching contribution element).
- Notification Date: GSK was advised of this allocation on January 28, 2016.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The scope is strictly limited to the disclosure of the PDMR transaction.
Key Facts for Investor Verification
- Verify the total number of shares held by Ms. C Thomas post-transaction to assess total insider ownership.
- Confirm the dividend reinvestment terms of the GSK 2009 Deferred Annual Bonus Plan Post-Tax.
- Note that this filing contains no financial results; refer to Form 20-F for comprehensive financial data.